Last Friday, Acesse, the Brazilian Association of Clinical Research Centers, organized its first event, and I had the privilege of participating representing SBMF - Brazilian Association of Pharmaceutical Medicine. During the event, I gave a lecture entitled Pharmaceutical Industry Pipeline – Therapeutic Areas in which Brazil has the best chance of participating in the coming years .
The Event
It was extremely positive to see a packed room, with clearly more than 200 people, including representatives from research centers from various regions of Brazil. With an audience composed of at least 60% of participants from research centers, the success of the event is evident.
The discussions covered were extremely relevant to the entire sector, covering not only research centers, but also the pharmaceutical and biotechnology industry, regulators, CROs and other service providers.
The Lecture
Talking about the industry pipeline is always an interesting challenge, as it forces us to investigate and understand where we are headed. Having worked in service provision for so long, especially in CROs, I believe this is an exercise that everyone in the industry should undertake.
Given the importance of the event and my enthusiasm for working closely with research centers, I made a point of preparing updated material and, more than that, I offered what I believe to be a guide with valuable references, based on data from the main consultancies in the sector.
Conclusion
It is clear that the movement to unite research centers through Acesse has the potential to reach all of Brazil. This scope can mean greater proximity between all players in the sector, strengthening clinical research in the country. The associative activity is always challenging, but the results, when achieved, are a source of great pride for all involved.
More than discussing the industry pipeline, the big message is: regardless of this pipeline, how prepared are research centers (and all of us) for the new technologies used in medicines and health products? How quickly will we be able to adapt to continue capturing good opportunities for the country? Will we be able to anticipate them?
The fact is that good management, based on indicators, with a structured quality system and the application of technology in the right measure, seems to be the ideal complement to good care practices and access to a pool of participants. Only this combination can generate sustainable results in the long term for research centers and for the industry. Clinical research continues to be essential for the evolution of the health system and for maintaining the quality of life of all of us.
Comments